Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
135.8 EUR | -0.10% | -1.98% | -3.29% |
01:00pm | New semester, new state of mind | |
06-28 | Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial | MT |
Sales 2024 * | 88.75B 82.75B 122B | Sales 2025 * | 92.26B 86.03B 127B | Capitalization | 352B 328B 483B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.96 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.81 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 131,900 |
Yield 2024 * |
3.3% | Yield 2025 * |
3.45% | Free-Float | 77.08% |
Latest transcript on Johnson & Johnson
1 day | -0.08% | ||
1 week | -1.98% | ||
Current month | -0.58% | ||
1 month | +0.52% | ||
3 months | -7.05% | ||
6 months | -3.29% | ||
Current year | -3.29% |
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-19 | 136 | +0.38% | 10 |
24-06-28 | 136.8 | -0.03% | 0 |
24-06-27 | 136.8 | -0.26% | 22 |
24-06-26 | 137.2 | -0.84% | 12 |
24-06-25 | 138.3 | -0.70% | 0 |
End-of-day quote Borsa Italiana, June 19, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+56.45% | 815B | |
+43.90% | 641B | |
+17.57% | 314B | |
+10.36% | 303B | |
+16.08% | 242B | |
+2.29% | 224B | |
+13.96% | 218B | |
+8.39% | 168B | |
-1.82% | 159B |
- Stock Market
- Equities
- JNJ Stock
- 4JNJ Stock